J 2023

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

BUSCA, Alessandro, Jon SALMANTON-GARCIA, Francesco MARCHESI, Francesca FARINA, Guldane Cengiz SEVAL et. al.

Basic information

Original name

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Authors

BUSCA, Alessandro, Jon SALMANTON-GARCIA (guarantor), Francesco MARCHESI, Francesca FARINA, Guldane Cengiz SEVAL, Van Doesum JAAP, Nick C DE JONGE, Nathan C BAHR, Johan MAERTENS, Joseph S MELETIADIS, Nicola S FRACCHIOLLA, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Luisa VERGA, Zdenek RACIL, Moraima JIMENEZ, Andreas GLENTHOJ, Ola BLENNOW, Alina Daniela TANASE, Martin SCHOENLEIN, Lucia PREZIOSO, Nina F KHANNA, Rafael F DUARTE, Pavel ZAK, Marcio NUCCI, Marina MACHADO, Austin KULASEKARARAJ, Ildefonso ESPIGADO, De Kort ELIZABETH, Jose-Maria Ribera-Santa SUSANA, Monia MARCHETTI, Gabriele MAGLIANO, Iker FALCES-ROMERO, Osman ILHAN, Emanuele AMMATUNA, Sofia ZOMPI, Panagiotis TSIRIGOTIS, Anastasia ANTONIADOU, Giovanni Paolo Maria ZAMBROTTA, Anna NORDLANDER, Linda Katharina KARLSSON, Michaela HANAKOVA, Giulia DRAGONETTI, Alba CABIRTA, Berg Venemyr CAROLINE, Stefanie GRAEFE, Van Praet JENS, Athanasios TRAGIANNIDIS, Verena PETZER, Alberto LOPEZ-GARCIA, Federico ITRI, Ana GROH, Eleni GAVRIILAKI, Michelina DARGENIO, Laman A RAHIMLI, Oliver A CORNELY and Livio PAGANO

Edition

Frontiers in immunology, LAUSANNE, Frontiers Media S.A. 2023, 1664-3224

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 7.300 in 2022

RIV identification code

RIV/00216224:14110/23:00130698

Organization unit

Faculty of Medicine

UT WoS

000951384400001

Keywords in English

allogeneic HSCT; COVID-19 infection; immunocompromised patients; SARS-CoV-2; hematological malignances

Tags

Tags

International impact, Reviewed
Změněno: 2/5/2023 10:47, Mgr. Tereza Miškechová

Abstract

V originále

BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. MethodsThis multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. ResultsThe median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). ConclusionsMortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.